托尔瓦普坦安全性评估:使用FAERS数据库进行现实世界的不良事件分析
Peiyang Cao1, Qian Wang1, Yan Wang1
1Department of Nephrology, The Fourth Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Frontiers in pharmacology
|January 24, 2025
概括
这项研究分析了与托尔瓦普坦相关的不良药物事件 (ADEs),揭示了肝胆,和代谢系统的关键风险. 临床医生应该在治疗期间监测这些ADE和潜在的瘤.
科学领域:
- 药监和药物安全 药监和药物安全
- 临床药理学 临床药理学
- 医疗数据分析 医学数据分析
背景情况:
- 托尔瓦普坦是一种用于特定疾病的药物,但其安全性需要持续评估.
- 药物不良事件 (ADEs) 是患者安全和药物管理的一个关键问题.
- 了解与托尔瓦普坦相关的现实世界ADEs对于知情的临床实践至关重要.
研究的目的:
- 系统地分析与tolvaptan相关的不良药物事件 (ADEs).
- 从大规模数据库中识别特征性和新型ADE信号.
- 为了评估与tolvaptan同时使用的药物.
主要方法:
- 从2009年第四季度到2024年第二季度利用了FDA不良事件报告系统 (FAERS) 数据库.
- 采用多个信号检测算法:报告几率比率 (ROR),比例报告比率 (PRR),贝叶斯信任传播神经网络和多项马鱼缩小器.
- 进行的同时服用药物的分析.
主要成果:
- 从7,486份ADE报告中确定了24个系统器官类别的196个首选术语.
- 典型的ADE包括肝胆道,/尿道和代谢/营养障碍.
- 值得注意的信号包括尿液度降低,透性脱髓化综合征和肺部瘤;还观察到脏囊破裂等新发现.
结论:
- 托尔瓦普坦虽然有益,但具有显著不良反应的风险.
- 密切的临床监测肝胆,,代谢疾病和瘤至关重要.
- 该研究强调了药物监测在识别和管理托尔瓦普坦相关的ADEs方面的重要性.
相关概念视频
Pharmacovigilance
770
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
770
Hazard Ratio
81
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
81
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Analysis of Population Pharmacokinetic Data
222
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
222
Clinical Trials: Overview
2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
43
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
43


